{"entity":{"id":"nct05736406","kind":"trial","name":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","aka":[],"tldr":"A phase 1/2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Hemerion Therapeutics, active and no longer recruiting.","summary":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma is a phase 1/2 interventional study registered as NCT05736406 by Hemerion Therapeutics, with 12 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2026-03-06. Interventions recorded: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2 and 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05736406","url":"https://clinicaltrials.gov/study/NCT05736406"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["aminolevulinic-acid"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05736406","phase":"1/2","setting":"An Interventional, Multicenter, and International Phase 1/2, Light-dose-escalation Study to Investigate the Safety and Feasibility of Intraoperative Photodynamic Therapy (PDT) With Pentalafen® Drug and Heliance® Solution Device in Male and Female Patients 18 to 75 Years of Age With Grade IV Glioblastoma.","sponsor":"Hemerion Therapeutics","enrolled":12,"outcomes":[]},"route":"/trials/nct05736406/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/"}]}}